How to Apply GLP-1 Overdose-Risk Data in Veterans With T2DM and OUD
How should clinicians use this study when choosing diabetes therapy for Veterans with type 2 diabetes and opioid use disorder?
Veterans with type 2 diabetes and opioid use disorder have substantial overdose risk, and clinicians may need to choose among several diabetes medications for a patient who also carries addiction-related vulnerability. This study offers an observational signal that semaglutide or tirzepatide may be associated with lower 12-month all-cause overdose risk than some, but not all, common comparator drugs in a VA population.
-
Confirm that the patient resembles the studied population
Apply these findings only to patients similar to those studied: Veterans receiving VA care with type 2 diabetes and opioid use disorder. In the study, OUD was identified by ICD coding from at least 1 inpatient or 2 outpatient encounters, and patients initiated semaglutide, tirzepatide, or another diabetes medication between January 1, 2020, and December 31, 2024.
-
Limit interpretation to patients with at least minimal early treatment persistence
The analyzed cohorts excluded patients with 30 days or less of cumulative prescription coverage or fewer than 2 fills starting on the index date. Use the results most directly for patients likely to maintain at least this level of early medication persistence, because the study did not evaluate patients who stopped after an initial prescription.
-
Compare semaglutide or tirzepatide against the specific alternative you are considering
Do not treat the findings as a class-wide advantage over all diabetes medications. Semaglutide and tirzepatide were collectively associated with significantly lower 12-month all-cause overdose rates than insulin and SGLT2 inhibitors, but not than metformin, sulfonylureas, or DPP4 inhibitors.
-
Use the signal as supportive information, not as proof of OUD efficacy
Frame the finding as an observational association relevant to medication selection in a patient with both T2DM and OUD. The article concludes that randomized controlled trials are still needed to determine whether semaglutide or tirzepatide are effective treatments for opioid use disorder and to establish causality.
-
Interpret the outcome as all-cause overdose risk
The study outcome was all-cause overdose over 12 months after medication initiation, not opioid overdose specifically. The authors used this broader outcome because opioid-only events were too few for adequate power, and many overdose cases lacked a specified substance.
-
Give more weight to the comparisons with stronger sensitivity analyses
The insulin and SGLT2 inhibitor comparisons were not only statistically significant after false-discovery control but also had E values of 5.70 and 7.46, respectively. The authors interpret this as meaning an unmeasured confounder would need very strong associations with both treatment assignment and overdose to fully explain away those findings, whereas the other comparisons were more sensitive to unmeasured confounding.
-
Avoid using the study to replace standard OUD care
This article does not test semaglutide or tirzepatide as substitutes for established opioid use disorder treatment. Continue usual OUD management and overdose monitoring, because the paper presents a preliminary signal rather than a validated OUD treatment protocol.
Clinical Considerations
- The study was observational, so residual unmeasured confounding may remain despite propensity score matching.
- The primary outcome was all-cause overdose rather than opioid overdose specifically, limiting direct inference about opioid-overdose prevention.
- The results apply most directly to patients with more than 30 days of cumulative prescription coverage and at least 2 fills, because patients with lower early persistence were excluded.
- Null comparisons with metformin, sulfonylureas, and DPP4 inhibitors were tempered by wide confidence intervals, and the authors note that metformin and DPP4 inhibitors may themselves have antiaddiction properties.
Bottom Line
When a Veteran with T2DM and OUD is otherwise a candidate for semaglutide or tirzepatide, this study supports discussing a possible all-cause overdose-risk advantage over insulin or SGLT2 inhibitors, but not treating GLP-1-based therapy as proven OUD treatment.
